IFCT-2402 LAG-MAPS A non-comparative phase IIR trial assessing fianlimab plus cemiplimab plus pemetrexed-platinum chemotherapy or cemiplimab plus pemetrexed-platinum chemotherapy for treatment-naive Pleural Mesothelioma (PM) patients
Latest Information Update: 21 Nov 2025
At a glance
- Drugs Cemiplimab (Primary) ; Fianlimab (Primary) ; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
Most Recent Events
- 21 Nov 2025 New trial record